







PRATHIMA C., SHASHIKUMARA, THIPPESWAMY T., JAYANTHI M. K. 
Dept. of Pharmacology, JSS Medical College (A Constituent College of JSS University), Mysore 
Email: samsruthia@gmail.com   
Received: 15 Mar 2016 Revised and Accepted: 22 Jul 2016 
ABSTRACT 
Objective: To evaluate the anticonvulsant activity of ethanolic extract of Mimosa pudica root (EMPR) in experimental mice models. 
Methods: Ethanolic extract of root parts of Mimosa pudica (EMPR) was prepared by a continuous method using soxhlet apparatus. EMPR in doses of 
1000, 2000 mg/kg body wt along with valproate were administrated to albino mice by oral route and anti-epileptic activity was assessed by 
maximal electroshock (MES) and pentylenetetrazole (PTZ) induced seizure models. Abolition of tonic hind limb extension phase and an increase in 
seizure latency period, when compared to control group, were taken as a measure of protection in MES and PTZ induced convulsion models 
respectively. 
Results: EMPR in the dose of 1000 and 2000 mg/kg body wt of mice showed significant anti-epileptic property in both MES and PTZ induced 
seizure models. There was a significant abolition of tonic hind limb extension phase in MES model. There was also a significant increase in seizure 
latency period in PTZ induced seizure model. 
Conclusion: Results suggest that ethanolic extract of Mimosa pudica roots possess significant anti-epileptic activity. Further investigations are 
required to determine its active constituents and also its antiepileptic mechanism of action. 
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‘Epilepsy’ is the commonest neuropsychiatric disorder characterized 
by paroxysmal cerebral dysrrhythmia, manifesting as brief episodes 
(seizures) of loss or disturbance of consciousness, with or without 
characteristic body movements (convulsions) with sensory or 
psychiatric phenomena [1]. There are about 50 million epileptic 
patients worldwide of whom up to 75% are living in the poor socio-
economic background with little or minimal access to medical 
services or therapy [2]. 
Seizures can be defined as brief episodes of signs and symptoms due 
to abnormal, excessive synchronous neuronal activity in the brain. 
Epilepsy can be idiopathic or secondary to infection, neoplasm or 
head injury. In some case, it may be hereditary [3]. Epilepsy is a 
major public health issue in many nations. Despite the massive scale 
of the problem and much research undertaken therapy of epilepsy 
remains poorly assumed [4]. 
Drug treatment of seizures/epilepsy at present is rather 
symptomatic. Drugs used for preventing the development of 
epilepsy or its cure are rather uncertain. Presently around 20 
approved allopathic drugs and several non-pharmacological options 
are available to treat epilepsy, but about 30 percent of the patients 
are refractory to these treatment. Research is undertaken to identify 
newer drugs for both symptomatic and preventive therapies [5]. 
Due to heterogeneity and limited understanding of this disease, 
discovery, and development of anti-epileptic drugs is difficult [4]. 
Many indigenous medical plants which are safer and well tolerated 
are used since ages for treating neurological diseases including 
epilepsy. Mimosa pudica plant belonging to the family Mimosae is 
known as ‘sensitive plant’ in English and ‘lajvanti’ or ‘chuimi’ in local 
Hindi language. The plant is distributed throughout India in the 
moist locality. It is a diffuse prickly under a shrub, of about 45-90 cm 
in height. Leaves are bipinnately compound; flowers are pink with 
globe heads, peduncles prickly usually in auxiliary pairs all along the 
branches. Fruits are bristly pods, flat and straw colored consisting of 
3-5 one-seeded segments [6]. 
Mimosa pudica contains mimosine [7] which is a toxic alkaloid. 
Adrenalin like substance has been identified in the extract of its 
leaves. Some workers have reported the presence of crocetin 
dimethyl easter in the extract of the plant. Roots contain tannin. 
Seeds contain a mucilage which is composed of d-xylose and d-
glucuronic acid. The plant is also reported to contain tubuline, and a 
new class of phytohormone ‘turgorines’. Mimosa pudica leaves 
extract is proven to contain various bioactive components such as 
terpenoids, flavonoids, glycosides, alkaloids, quinines, phenols, 
tannins, saponins and coumarins [8]. 
Ayurveda has proved that its root is bitter, acrid, coolant, vulnerary, 
alexipharmic and used in the treatment of leprosy, dysentery, 
vaginal and uterine complaints, inflammations, asthma, leucoderma, 
fatigue and blood diseases [8]. It is also used for the treatment of 
anxiety and depression [9]. Alcoholic extract of Mimosa pudica 
leaves has been proved to possess anti-epileptic activity in previous 
studies [10]. Hence, the present study is undertaken with an 
alcoholic extract of Mimosa pudica root to explore its antiepileptic 
potential. 
MATERIALS AND METHODS 
Chemicals 
Ethanol, Pentylenetetrazole (PTZ, Sigma laboratory), Propylene 
glycol, Valproic acid (Sun pharmaceuticals). 
Preparation of the extract 
Mimosa pudica plant was collected along with roots from around 
Mysore district and authenticated by the Pharmacognosy 
department of JSS Pharmacy College, Mysore. The roots were 
separated and made into a coarse powder after a shade dry for 1 w. 
About 500grams of this powder was subjected to soxhlet extraction 
for 12 h using ethanol as a solvent. The extract was further 
concentrated using vacuum extractor for complete removal of the 
ethanol. The concentrated ethanolic extract of Mimosa pudica root 
(EMPR) was dissolved in vehicle propylene glycol for oral 
administration to the animals. 
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Adult Swiss albino mice of either sex weighing between 25 to 30g 
were randomly selected from Central animal facility of JSS Medical 
College, Mysore. Animals were housed in 5 groups of 6 each, at an 
ambient temperature of 25±1°C with ad libitum access to food and 
water. The animals were fasted overnight just prior to the 
experiment but allowed free access to drinking water and food. 
Grouping 
Animals were randomly divided into 5 groups of 6 each.  
Group 1: Control group received 0.25 ml propylene glycol p. o. 
Group 2: Standard group received 200 mg/kg Valproate p. o. [11]  
Group 3: Test group 1-received 1000 mg/kg of EMPR p. o.  
Group 4: Test group 2-received 2000 mg/kg of EMPR p. o. 
Group 5: Test group 3-received 1000 mg/kg of EMPR+70 mg/kg 
Valproate p. o. 
All the drugs were administered orally for 5 d. The experimental 
seizures were induced on 5th
The tonic-clonic convulsions were induced by maximal electroshock 
using an electroconvulsiometer (INCO, Ambala, India) by passing an 
alternating electric current of 50 Hz and 150 mA for 0.2 seconds 
through ear clip electrodes. The animals were preliminarily 
screened and the mice which showed the extension of hind limb 
upon electric shock were included in the study. All the drugs and 
propylene glycol were administered one hour prior to induction of 
convulsion. The duration of tonic hind limb flexion (THLF), tonic 
hind limb extension (THLE), clonus and stupor were noted. The 
vehicle treated mice showed the characteristic extensor tonus. The 
abolition of extensor (tonic) phase in drug treated groups was taken 
as criteria for their anticonvulsant activity. 
 day of the experiment. The Institutional 
Animal Ethical Committee approval was obtained prior to the 
experimentation. 
Phytochemical screening 
The freshly prepared extract of the roots of Mimosa pudica was 
subjected to phytochemical screening tests for the detection of 
various constituents [12]. 
Acute toxicity study 
The animals were treated with increasing doses of the ethanolic 
extract (EMP): 0.5, 1, 2, 4 and 5 g/kg p. o. The toxicity studies were 
conducted according to the OECD 423 guidelines [13]. All the treated 
animals were observed for any abnormal or toxic manifestations and 
mortality.  
Anti-epileptic models [14] 
Maximal electroshock-induced seizures (MES) in mice 
Pentylenetetrazole (PTZ) induced seizures in mice 
The albino mice were selected two weeks prior to the experiment by 
injecting the Pentylenetetrazole in a dose of 30 mg/kg intraperitoneally. 
Only those mice which showed clonic convulsions within 30 min during 
the preliminary examination were chosen for the study. After one hour 
of drug treatment, PTZ (70 mg/kg) was injected intraperitoneally and 
animals were observed for clonic convulsion episode. The clonic 
convulsions onset time, duration of clonic convulsions and postictal 
depression were observed for a period of 30 min.  
Statistical analysis 
The results were computed using GRAPH PRISM PAD version 5. One 
way Anova test followed by Post-hoc Tukeys multiple comparison 
tests were applied using the software. The differences between 
means were considered to be significant at p<0.05. The results were 
tabulated as below. 
RESULTS 
Phytochemical screening 
Phytochemical screening of EMPR showed that the crude extract 
contained tannins, alkaloids, terpenoids, flavonoids, sterols, phenolic 
compounds and proteins. 
Acute toxicity study 
There was no mortality amongst the mice treated with the graded 
dose of EMPR up to a dose of 5000 mg/kg for a duration of 72 h. 
EMPR dose-dependently protected the mice against the MES and 
PTZ induced seizures. At the dose of 500 mg/kg and 4000 mg/kg p. 
o, the EMPR provided respectively 23% and 100% protection 
against seizures in PTZ induced seizures model. Based on the 
preliminary toxicity data and logarithmic dose-response curve, the 
EMPR dose of our further study was determined between 1000 to 
4000 mg/kg.  
MES-induced seizure model 
The average duration of tonic hind limb flexion (THLF), tonic hind 
limb extension (THLE), clonus and stupor along with the 
percentages of inhibition of convulsions are presented in table 1. 
 
Table 1: Effect of ethanolic extract of M. Pudica (EMPR) on MES-induced seizures in mice 








% inhibition of 
convulsion 
I Vehicle control 8.45±0.57 9.15±0.50 18.65±0.80 319.8±3.89  -- 
II Valproate(200 mg/kg) 3.2±0.66**** 1.98±0.28**** 9.63±1.31*** 80.35±3.67**** 78.36% 
III EMPR (1000 mg/kg) 5.7±0.57** 5.27±0.14**** 13.05±1.06* 118.2±2.84**** 42.41% 
IV EMPR (2000 mg/kg) 4.53±0.37*** 4.36±0.42**** 12.03±1.4* 109.2±2.98**** 52.35% 
V EMPR+Valproate  
(1000 mg/kg+70 mg/kg) 
3.9±0.41**** 2.14±0.26**** 10.23±1.73*** 92.33±3.11**** 76.61% 
Values are expressed as mean±SEM. Comparison between control v/s all the other groups. Statistical test done by one-way ANOVA followed by 
Post-hoc Tukey’s multiple comparison test, *p<0.05, **p<0.01; *** p<0.001; ****p<0.0001. 
 
Albino mice pretreated with EMPR at the doses of 1000 and 2000 
mg/kg exhibited a significant delay in the onset time and also a 
significant decrease in duration of THLF, THLE, clonus and stupor 
phases when compared to the control group mice. The albino mice 
pretreated with EMPR at doses of 1000 and 2000 mg/kg also 
exhibited significant protection from convulsion induced by 
electroshock method in a dose-dependent manner. The animal 
group treatment with a combination of both 1000 mg/kg of EMPR 
and low dose (70 mg/kg) of valproate exhibited significant anti-
epileptic activity comparable to the Standard Valproate (200 mg/kg) 
treated group.  
Pentylenetetrazole (PTZ) induced seizure model 
The average seizure latency time, duration of myoclonic jerks, 
Generalized clonic seizures and post-ictal depression along with the 
percentages of protection against convulsions are presented in table 
2. Albino mice pretreated with EMPR at the doses of 1000 and 2000 
mg/kg and the combination group exhibited a significant delay in 
the onset time of clonic seizures when compared to the control 
group mice. EMPR (1000 and 2000 mg/kg) treated mice also 
showed a significant decrease in number and duration of myoclonic 
jerks, clonic seizures and duration of postictal depression when 
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compared to the control group mice. EMPR provided significant 
protection from convulsion induced by PTZ in a dose-dependent 
manner. The animal group treatment with a combination of both 
1000 mg/kg of EMPR and low dose (70 mg/kg) of valproate 
exhibited a significant anti-epileptic activity even better than the 
Standard Valproate (200 mg/kg) treated group. 
 





Duration of-of myoclonic 
jerks (sec) 






I-Vehicle control 308.6±25.81 6.72±0.48 14.2±0.66 322.6±9.82 -- 
II-Valproate 











































Values are expressed as mean±SEM. PID: Postictal depression; Comparison between control vs all the other groups. Statistical test is done by one-
way ANOVA followed by Post-hoc Tukey’s multiple comparison tests. *p<0.05, **p<0.01; *** p<0.001; ****p<0.0001. 
 
DISCUSSION 
Epilepsy is a group of chronic neurological disorder characterized by 
episodes of convulsive seizures, sensory disturbance, altered 
consciousness or all of these symptoms resulting from a brain 
dysfunction or an abnormal discharge of cerebral neurons [15]. The 
currently available AEDs for the therapy of epilepsy are associated 
with various side effects like teratogenicity and chronic toxicities of 
various organs. This has necessitated the need for a safer alternative 
indigenous drugs for the pharmacotherapy of epilepsy. 
Various plant preparations are used by the folklore and the tribals 
for the treatment of common disease conditions including epilepsy. 
Mimosa pudica is one of those commonly seen plants which is known 
to possess analgesic, anti-anxiety, antidepressant, anti-asthmatic 
and aphrodisiac properties [8]. Phytochemical screening of the 
EMPR extract revealed the presence of tannins, alkaloids, 
terpenoids, flavonoids, sterols, phenolic compounds and proteins. 
The data obtained from the present study demonstrated that EMPR 
significantly inhibited the convulsions induced by MES and PTZ. 
GABA is known to be a major inhibitory neurotransmitter in the 
brain and glutamate the excitatory neurotransmitter. GABA acts on 
GABA receptors while glutamate acts on NMDA and non-NMDA 
receptors. These receptors are known to modify various ion 
channels like Na+, K+, Ca++or Cl-and thereby influence the neuronal 
activity [16]. Abnormalities in the GABAergic system have been 
implicated in various neurological and psychological diseases such 
as anxiety, panic attacks, schizophrenia, huntington's chorea and 
epilepsy. Decreased function of GABAA 
MES test in mice primarily indicates the compounds which are 
effective in grand mal epilepsy. The tonic extension of the hind limb 
evoked by electrical stimuli is suppressed by anti-epileptics. Anti-
epileptic drugs that block MES-induced seizure are known to act by 
blocking the seizure spread [17]. The drugs which antagonize the 
PTZ induced convulsions are known to be effective in petitmal 
epilepsy. PTZ is known to possess GABA antagonistic activity [18]. 
The antiepileptic drugs diazepam and phenobarbitone are proved to 
produce their antiepileptic effects by enhancing GABA-mediated 
inhibition in the brain. Valproate is known to act by multiple 
mechanisms: prolongation of Na
synapses is known to be one 
of the important factors for epileptogenesis [14].  
+channel inactivation-like 
phenytoin, attenuation of T-type Ca++
Previous studies have demonstrated the antiepileptic activity of 
decoction of Mimosa pudica leaves at the doses of 1000-4000 mg/kg 
i. p in pentylenetetrazole and strychnine induced seizure models 
[20]. Also in another study, an alcoholic extract of leaves of Mimosa 
pudica in the dose of 50, 100 and 200 mg/kg given orally suppressed 
the MES-induced seizures in albino rats [10]. 
currents like ethosuximide and 
by augmenting GABA transmission. It is known to inhibit both PTZ 
and MES-induced convulsions [19].  
The present revealed that EMPR possesses a dose-dependent 
protection against-tonic extensor phase in MES-induced seizure 
model and seizure latency in PTZ induced seizure model. EMPR 
showed a better anticonvulsant activity in the PTZ model than MES 
anti-epileptic model. The EMPR combined with the low dose of 
valproate (70 mg/kg) showed a similar anticonvulsant activity as 
the standard dose of valproate (200 mg/kg). This combination of 
low doses of EMPR and Valproate is beneficial as it reduces the 
incidences and severity of undue side effects of the drugs.  
The phytochemical screening of the extract revealed the presence of 
tannins, alkaloids, triterpenoids, flavonoids, sterols, phenolic 
compounds and proteins. Based on the present knowledge of the 
chemical constituents it is not possible to attribute with certainty 
the detected active principle/s for its anticonvulsant activity. 
However, several flavonoids could act as benzodiazepine-like 
molecules in the central nervous system and modulate GABA-
mediated chloride channels in animal models of anxiety, sedation 
and convulsion. Certain triterpenic steroids are reported to possess 
anticonvulsant activity in MES and PTZ experimental seizure models 
[21]. Further studies are required for isolation of bioactive 
principles responsible for these activities. These findings justify the 
traditional use of this plant in the control and treatment of 
convulsions and epilepsy.  
CONCLUSION 
It can be concluded from the study that the ethanolic extract Mimosa 
pudica root (EMPR) exhibited significant antiepileptic activity in 
both MES and PTZ induced seizure models. Further studies are 
needed to evaluate the precise mechanism/s, bioactive principles 
and safety profile of the plant as a medicinal remedy for convulsive 
disorders.  
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